<DOC>
	<DOCNO>NCT03079323</DOCNO>
	<brief_summary>Prospective non-randomized phase 2 trial study efficacy additional elective para-aortic RT ( PART ) pN1 patient compare historically treat adjuvant whole pelvic radiotherapy ( WPRT ) alone .</brief_summary>
	<brief_title>Trial Investigate Benefit Elective Para-Aortic Radiotherapy ( PART ) pN1 Prostate Cancer</brief_title>
	<detailed_description>Rationale : In prostate cancer histopathologically proven pelvic lymph node metastasis ( pN1 ) extend pelvic lymph node dissection , multimodality treatment consist treatment primary tumor , androgen deprivation therapy whole pelvic radiotherapy offer best result standard-of-care . However , case &gt; 1 pelvic lymph node invade tumor , extend pelvic lymph node dissection , 40 % patient relapse biochemically clinically . Clinical relapse present para-aortic lymph node ( M1a disease ) 25 % case observed series . Therefore Elective Para-Aortic Radiotherapy ( PART ) may improve disease control . Objective : The main goal phase II study investigate whether elective para-aortic radiotherapy increase clinical relapse-free survival ( cRFS ) define absence clinical relapse ( cR ) biological image 5 year . The secondary objective study : acute toxicity , late toxicity , quality life ( QoL ) , time palliative androgen deprivation therapy ( ADT ) , time castration refractory prostate cancer ( CRPC ) , cause-specific survival field pelvic para-aortic disease control . Study design : The PART-trial non-randomized phase II trial . Study population : Men histological proven adenocarcinoma prostate ( cT1-4 ; pT2-4 ) presence pN1 disease ePLND eligible study . For trial-inclusion , pN1 disease define basis one follow criterion : ( 1 ) two positive LN ; ( 2 ) ratio positive LN / remove LN &gt; 7 % ; ( 3 ) presence extracapsular LN extension . Patients refer external beam radiotherapy ( EBRT ) fulfill inclusion criterion without exclusion criterion include present trial write informed consent . Intervention : Patients include PART-trial receive radiotherapy prostate prostate bed pelvic lymph node accord current standard . Furthermore patient PART-trial receive additional elective radiation para-aortic lymph node . The total radiation dose deliver para-aortic lymph node area 45 Gy 25 fraction 1.8 Gy . Androgen deprivation therapy foreseen trial 24 month ( long term ) . Main study parameters/endpoints : The primary endpoint evaluate whether addition elective para-aortic irradiation pN1 prostate cancer patient increase clinical relapse-free survival ( cRFS ) define absence clinical relapse ( cR ) biological image 5 year . Clinical relapse-free survival define combination PSA measurement image . Secondary endpoint acute late gastrointestinal ( GI ) genitourinary ( GU ) toxicity use Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0 , QoL , time palliative ADT , time CRPC , cause-specific survival field pelvic para-aortic disease control .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Signed informed consent willingness comply treatment followup Diagnosis histopathologically confirm prostate cancer No former treatment prostate cancer Presence pN1 disease ePLND ( criterion define protocol ) Age &gt; 18 Karnofsky Performance score &gt; 70 Ability understand inform consent ( Helsinki Declaration ) Recurrent disease status Presence cM1a , cM1b cM1c disease Former radiotherapy make WPRT and/or PART impossible Prior malignancy , diseasefree &gt; 5 year , except basocellular skin epithelioma Severe active comorbidity likely impact feasibility WPRT and/or PART Disorder preclude understanding trial information</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>External beam radiotherapy</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Elective para-aortic radiation therapy</keyword>
	<keyword>PART</keyword>
</DOC>